GSK sued by inventors of Relenza anti-flu drug
Thursday 06 May 2004
GlaxoSmithKline IS being sued by the Australian inventors of its controversial flu treatment Relenza, who accuse the giant drug maker of failing to properly promote the product.
The Melbourne-based biotech group Biota, which licensed Relenza in 1990 to what was then Glaxo, says it has been driven to the courts after two years of fruitless negotiations with GSK. The product failed to live up to its early promise and had sales last year of less than £10m, despite being approved in 70 countries.
"Relenza was a breakthrough influenza drug that had great potential but it was effectively abandoned at birth," Biota's chief executive, Peter Molloy, said. The company says GSK breached the terms of its licensing deal by failing to launch Relenza in a number of countries, by dropping further studies that may have widened its use, and by not pursuing fully ways to improve the inhaler used for taking the drug. It is demanding unspecified damages, which could total up to $100m (£56m).
GSK said it was surprised by Biota's lawsuit but would not comment further.
The high hopes for Relenza began to falter when the National Institute for Clinical Excellence, the NHS's arbiter of value for money, ruled that the drug would only marginally improve the treatment of flu and should be prescribed only in very limited circumstances. It was a ruling that infuriated Sir Richard Sykes, then chairman of Glaxo Wellcome, so much that he threatened to move the company's headquarters to the US.
Biota is aggrieved that Relenza was sidelined after the merger of Glaxo Wellcome with SmithKline Beecham to create GSK in 2000. GSK has been arguing in private that it pulled applications to launch the drug as a prevention for flu after it became clear it would not get approval in the US.
Relenza was discovered by Biota scientists in 1989 and was the first in a new generation of anti-flu drugs, called neuraminidase inhibitors, which are effective against both major strains of influenza.
However, the fact that it has to be used with an inhaler put it at an immediate disadvantage to a rival pill from Roche, the Swiss pharmaceuticals giant.
- 1 Mario Balotelli: Staff at arson-hit Manchester Dogs' Home convinced Liverpool striker is behind five-figure donation
- 2 Friends 20th anniversary: Alison Jackson photographs reunited cast
- 3 A bottle of wine a day is not bad for you and abstaining is worse than drinking, scientist claims
- 4 The response to my Pizza Express review has been overwhelming, and taught me a lot about journalism
- 5 Free U2 album: How the most generous giveaway in music history turned into a PR disaster
Scottish independence: Despite defeat history may still point to Alex Salmond as the victor
Scottish independence referendum: Frankie Boyle reacts to nation's 'No' vote - 'To be fair, I've always hated Scotland'
Iranian blogger found guilty of insulting Prophet Mohammad on Facebook sentenced to death
Scottish referendum: Police struggle to control Unionist rally in Glasgow's George Square
Hitler’s former food taster reveals the horrors of the Wolf’s Lair
Daniele Watts: Django Unchained actress detained by Los Angeles police after being mistaken for a prostitute
Scottish independence referendum: A nation divided against itself
Scottish referendum results: Cross-party consensus collapses amid Tory-Labour spat on the 'English question'
Scottish independence: David Cameron is becoming the 'George Bush of Britain'
Russia freezes Ukraine into submission: Kiev admits country doesn't have enough fuel for winter
Scottish independence: The Queen breaks silence on referendum debate – as think tank warns of £14bn black hole if Scotland votes Yes
iJobs Money & Business
£400 - £450 Per Day: Clearwater People Solutions Ltd: **URGENT CONTRACT ROLE**...
Up to £100k or £450p/d: Saxton Leigh: My client is a leading commodities tradi...
£320 - £330 per day: Ashdown Group: The Ashdown Group have been engaged by a l...
To £75,000 + Pension + Benefits + Bonus: Saxton Leigh: My client is looking f...